Dynamic contrast-enhanced MRI of primary rectal cancer: Quantitative correlation with positron emission tomography/computed tomography

2011 ◽  
Vol 33 (2) ◽  
pp. 340-347 ◽  
Author(s):  
Jing Gu ◽  
Pek-Lan Khong ◽  
Silun Wang ◽  
Queenie Chan ◽  
Ed X. Wu ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Rectal Cancer ◽  
Emission Tomography ◽  
Quantitative Correlation ◽  
Dynamic Contrast Enhanced ◽  
Primary Rectal Cancer ◽  
Positron Emission ◽  
Contrast Enhanced ◽  
Contrast Enhanced Mri

Does Positron Emission Tomography Change Management in Primary Rectal Cancer? A Prospective Assessment

2004 ◽  
Vol 47 (4) ◽  
pp. 451-458 ◽  
Author(s):  
Alexander G. Heriot ◽  
Rodney J. Hicks ◽  
Elizabeth G. P. Drummond ◽  
Jamie Keck ◽  
John Mackay ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Rectal Cancer ◽  
Change Management ◽  
Emission Tomography ◽  
Primary Rectal Cancer ◽  
Positron Emission ◽  
Prospective Assessment

scholarly journals Comparison of Contrast-Enhanced Ultrasound and Positron Emission Tomography/Computed Tomography (PET/CT) in Lymphoma

2018 ◽  
Vol 24 ◽  
pp. 5558-5565 ◽  
Author(s):  
Xiaoyan Niu ◽  
Wenbin Jiang ◽  
Xiaojuan Zhang ◽  
Zhaoyan Ding ◽  
Hongwei Xue ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Contrast Enhanced Ultrasound ◽  
Positron Emission ◽  
Contrast Enhanced ◽  
Pet Ct

scholarly journals Prospective Study on the Performance of 18F-DOPA Positron Emission Tomography/Computed Tomography in Patients with Medullary Thyroid Carcinoma

2022 ◽  
Author(s):  
Inés Califano ◽  
Fabian Pitoia ◽  
Roxana Chirico ◽  
Alejandra de Salazar ◽  
Maria Bastianello
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Distant Metastases ◽  
Emission Tomography ◽  
Medullary Thyroid ◽  
Contrast Enhanced Ct ◽  
Positron Emission ◽  
Contrast Enhanced ◽  
Pet Ct ◽  
Enhanced Ct

Abstract Purpose 18F-DOPA Positron Emission Tomography/Computed Tomography (18F-DOPA PET/CT) is a sensitive functional imaging method (65-75%) for detecting disease localization in medullary thyroid cancer (MTC). We aimed: i) to assess the clinical usefulness of 18F-DOPA PET/CT in patients with MTC and elevated calcitonin (Ctn) and CEA levels and, ii) to evaluate changes in disease management secondary to the findings encountered with this methodology. Methods thirty-six patients with MTC and Ctn levels ≥150 pg/ml were prospectively included. Neck ultrasound, chest contrast-enhanced CT, liver magnetic resonance imaging/ abdominal 3-phase contrast-enhanced CT and bone scintigraphy were carried out up to 6 months before the 18F DOPA PET/CT. Results 77.7% were female and 27% had hereditary MTC. Median Ctn level was 1450 pg/ml [150-56620], median CEA level 413 ng/ml [2.9-7436]. Median Ctn DT was 37.5 months [5.7-240]; median CEA DT was 31.8 [4.9-180]. 18F-DOPA PET/CT was positive in 33 patients (91.6%); in 18 (56%) uptake was observed in lymph nodes in the neck or mediastinum, in 7 cases (22%) distant metastases were diagnosed, and in 8 additional patients (24%) both locoregional and distant sites of disease were found. Ctn and CEA levels were higher in patients with ≥ 3 foci of distant metastases. In 14 patients (38.8%), findings on 18F-DOPA PET/CT led to changes in management; surgery for locoregional lymph nodes was the most frequent procedure in 8 patients (22%). Conclusion 18F-DOPA PET/CT was useful for the detection of recurrent disease in MTC and provided helpful information for patient management.

Sign in / Sign up

Export Citation Format

Share Document